Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology. (24th April 2019)

• Record Type: Journal Article
• Authors: Nair, Pooja; Prado, Maricela; Perea-Gil, Isaac; Karakikes, Ioannis
• Is Part Of: Stem cells translational medicine. Volume 8:Number 8(2019)
• Page Start: 758
• Page End: 767
• Publication Date: 2019-04-24
• Subjects: Cancer -- Cardiac -- Chemotherapy -- Induced pluripotent stem cells -- Toxicity; Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.1002/sctm.18-0279
• Languages: English
• ISSNs: 2157-6564

Abstract

Abstract: As common chemotherapeutic agents are associated with an increased risk of acute and chronic cardiovascular complications, a new clinical discipline, cardio-oncology, has recently emerged. At the same time, the development of preclinical human stem cell-derived cardiovascular models holds promise as a more faithful platform to predict the cardiovascular toxicity of common cancer therapies and advance our understanding of the underlying mechanisms contributing to the cardiotoxicity. In this article, we review the recent advances in preclinical cancer-related cardiotoxicity testing, focusing on new technologies, such as human induced pluripotent stem cell-derived cardiomyocytes and tissue engineering. We further discuss some of the limitations of these technologies and present future directions. Stem Cells Translational Medicine 2019;8:758–767 : Abstract : Personalized chemotherapy drug screening to minimize cardiotoxicity. (1) Peripheral blood mononuclear cells taken from the cancer patient. (2) Peripheral blood mononuclear cells reprogrammed to human induced pluripotent stem cells. (3) Human induced pluripotent stem cells differentiated into cardiomyocytes. (4) Chemotherapy agents screened for toxicity on tissue derived from these cardiomyocytes—engineered heart tissue, organ-on-a-chip, organoid, and cardiac organoid chamber. (5) Single drug with minimal cardiotoxic effects selected from initial drug screen. (6) Tailored therapy for individual patient based on in vitro screening.